Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a late-stage biopharmaceutical company, announces its participation in NobleCon18, scheduled for April 19-21, 2022. Executive Chairman Leonard Mazur will present on April 20 at 1:30 p.m. EST, discussing recent business advancements and future milestones. The conference will occur at Hard Rock Hotel & Casino in Hollywood, Florida. Citius focuses on critical care products, including Mino-Lok® and I/ONTAK (E7777). Mino-Lok has Fast Track designation from the FDA and targets catheter-related bloodstream infections.
- None.
- None.
CRANFORD, N.J., April 14, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products in oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will present at NobleCon18, Noble Capital Markets' 18th Annual Investor Conference being held April 19-21, 2022. Leonard Mazur, Executive Chairman of Citius, will discuss recent business developments and upcoming milestones.
NobleCon18 Conference | |
Date: | Wednesday, April 20, 2022 at 1:30 p.m. EST |
Breakout sessions: | |
Wednesday, April 20 at 12:15 p.m. | |
Thursday, April 21 at 10:00 a.m. | |
Location: | Hard Rock Hotel & Casino, Hollywood, Florida |
Registration: | Visit the conference website |
Available beginning April 21 for 90 days; archived under "Events" in the Investors section of the Citius website | |
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed its Pivotal Phase 3 trial. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS) associated with COVID-19. For more information, please visit www.citiuspharma.com.
Investor Relations for Citius Pharmaceuticals:
Ilanit Allen
Vice President, Investor Relations and Corporate Communications
T: 908-967-6677 x113
E: ir@citiuspharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-noblecon18-investor-conference-on-april-20-2022-301525676.html
SOURCE Citius Pharmaceuticals, Inc.
FAQ
What is the date of Citius Pharmaceuticals' presentation at NobleCon18?
Where is the NobleCon18 conference being held?
Who will represent Citius Pharmaceuticals at NobleCon18?
What are the main topics Citius Pharmaceuticals will discuss at the conference?
What is Mino-Lok® and its significance for Citius Pharmaceuticals?
What FDA designations have been granted to Citius Pharmaceuticals' products?
